康为世纪：2025年年度业绩预亏，净利润同比减亏28.91%-41.83%

Core Viewpoint - The company expects a reduction in net loss for the fiscal year 2025, with projections indicating a net profit attributable to the parent company ranging from -111.76 million to -91.44 million, representing a year-on-year decrease in loss of 28.91% to 41.83 [1] Financial Performance - The projected non-GAAP net profit is expected to be between -143.30 million and -122.98 million, showing a year-on-year decrease in loss of 20.64% to 31.90% [1] - The previous year's net profit attributable to the parent company was -157.21 million, and the non-GAAP net profit was -180.57 million [1] Industry Context - The primary reason for the ongoing losses is that the life sciences and diagnostic reagents industry is in a recovery phase, and new business ventures have not yet achieved economies of scale [1] - The reduction in net profit loss is attributed to an increase in main business revenue and rapid growth in technology service operations [1]